Could Galectin Therapeutics, Inc. (GALT) Skyrocket Even More? The Stock Just Made 52-Week High

June 18, 2018 - By Louis Casey

Galectin Therapeutics, Inc. (NASDAQ:GALT) Logo

Investors sentiment increased to 1.86 in 2018 Q1. Its up 1.33, from 0.53 in 2017Q4. It is positive, as 7 investors sold Galectin Therapeutics, Inc. shares while 7 reduced holdings. 17 funds opened positions while 9 raised stakes. 4.02 million shares or 30.74% more from 3.08 million shares in 2017Q4 were reported.
Manufacturers Life Company The has invested 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Norris Perne And French Ltd Liability Partnership Mi accumulated 10,500 shares. Bluecrest Cap Management Limited has invested 0.01% in Galectin Therapeutics, Inc. (NASDAQ:GALT). State Street has 17,450 shares for 0% of their portfolio. 23,593 are held by Lpl Ltd. Jefferies Gp Ltd Llc accumulated 20,000 shares. Da Davidson And invested in 731,300 shares or 0.07% of the stock. Barclays Public Limited Com holds 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT) or 20,123 shares. Tci Wealth Advsrs accumulated 0% or 300 shares. Sabby Lc holds 143,400 shares. Geode Mgmt Ltd Liability Corp holds 195,411 shares or 0% of its portfolio. Sei has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Blackrock Incorporated stated it has 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Element Mgmt Limited Com owns 14,144 shares for 0% of their portfolio. Citadel Advsr Limited Liability Corporation invested in 67,546 shares.

Since January 25, 2018, it had 2 buys, and 21 insider sales for $12.51 million activity. 2,000 shares were bought by FREEMAN KEVIN D, worth $8,191. Another trade for 100,000 shares valued at $751,000 was sold by TRABER PETER G. $256,081 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) was sold by CZIRR JAMES C on Friday, June 1. $646,800 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) was sold by 10X Fund – L.P. on Friday, June 8. Shares for $65,167 were sold by CALLICUTT JACK W on Wednesday, June 13. 4,000 Galectin Therapeutics, Inc. (NASDAQ:GALT) shares with value of $14,320 were sold by ZUCCONI THEODORE DANIEL.

The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) hit a new 52-week high and has $9.58 target or 4.00 % above today’s $9.21 share price. The 6 months bullish chart indicates low risk for the $347.59 million company. The 1-year high was reported on Jun, 18 by If the $9.58 price target is reached, the company will be worth $13.90M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 5.26% or $0.46 during the last trading session, reaching $9.21. About 2.70M shares traded or 286.00% up from the average. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 77.97% since June 18, 2017 and is uptrending. It has outperformed by 65.40% the S&P500.

Analysts await Galectin Therapeutics, Inc. (NASDAQ:GALT) to report earnings on August, 13. They expect $-0.14 EPS, 0.00 % or $0.00 from last year’s $-0.14 per share. After $-0.12 actual EPS reported by Galectin Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 16.67 % negative EPS growth.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: which released: “Galectin Therapeutics Inc. Announces New CEO” on June 12, 2018, also with their article: “Mid-Day Market Update: Pivotal Software Gains Following Q1 Results; Flex Pharma Shares Slide” published on June 13, 2018, published: “3 NASH Stocks That Could Soar in the Second Half of 2018” on June 15, 2018. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: and their article: “Galectin Therapeutics’s Market Value Should Soar In The Coming Months” published on June 07, 2018 as well as‘s news article titled: “3 Biotech Stocks That Soared This Week: Are They Buys?” with publication date: June 16, 2018.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $347.59 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: